Furiex Pharmaceuticals, Inc. (FURX) Confirms Takeda Pharmaceutical Co. Ltd. (TKPYY) Receives Positive CHMP Opinion for VIPIDIA (alogliptin) and Fixed-Dose Combinations VIPDOMET (alogliptin and metformin) and INCRESYNC (alogliptin and pioglitazone)
7/26/2013 10:06:30 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
MORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today confirmed that Takeda Pharmaceutical Company Limited (Takeda) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion for VIPIDIA™ (alogliptin) and Fixed-Dose Combinations VIPDOMET™ (alogliptin and metformin) and INCRESYNC™ (alogliptin and pioglitazone) for the treatment of Type 2 diabetes patients who are uncontrolled on existing therapies. This opinion is a key step toward getting marketing authorization in EU countries, Norway and Iceland.
Help employers find you! Check out all the jobs and post your resume.
comments powered by